Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2527471 | Clinical Therapeutics | 2013 | 20 Pages |
Abstract
The findings from the preclinical studies suggest that the LX4211 + sitagliptin combination produced synergistic increases in active GLP-1 after a meal challenge containing glucose. These initial clinical results also suggest that a LX4211 + DPP-4 inhibitor combination may provide an option in patients with T2DM. The potential long-term clinical benefits of such combination treatment need to be confirmed in large clinical trials. ClinicalTrials.gov identifier: NCT01441232.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Brian PhD, Zhi-Ming MD, PhD, Ike MD, Kenny BS, Phillip MS, Anne BA, Joel MD, Melinda BS, Dennis MD, Arthur MD, PhD, David MD,